Immunotherapy in Melanoma: Recent Advances and Future Directions (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 1504
Special Issue Editors
Interests: melanoma; immunotherapy; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Interests: melanoma; immunotherapy; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of a previous Special Issue entitled “Immunotherapy in Melanoma: Recent Advances and Future Directions” (https://www.mdpi.com/journal/cancers/special_issues/IM).
Looking beyond the pandemic, immune-checkpoint inhibitors (ICIs) continue to offer long-term remission in melanoma, either in an adjuvant or a metastatic setting. At the same time, the development of new immunotherapeutic agents (e.g., relatlimab and bempegaldesleukin) or combinatorial regimens (e.g., immune/targeted combinations, intralesional infusions and ICIs) and the identification of intratumoral or circulating biomarkers continue to open new horizons and produce new questions for immune-mediated treatments. Issues such as the duration and the exact dose of anti-PD1/anti-PDL1 and anti-CTLA4 agents in metastatic and locoregional disease, the stage of early melanoma that should be treated with ICIs and the potential of intralesional infusions are still under consideration and an open field for debate. To this end, this Special Issue of Cancers aims to explore the constantly remodeled area of immunotherapy in melanoma management in the post-COVID-19 era and tries to recap where we are and where we are going in terms of the knowledge on immune-mediated therapies in melanoma.
We look forward to receiving your contributions.
Dr. Dimitrios C. Ziogas
Prof. Dr. Helen Gogas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- immunotherapy
- prognostic and predictive biomarkers
- recurrence-free and overall survival
- adjuvant/neoadjuvant immunotherapy
- anti-PD1/anti-PD-L1 and anti-CTLA4 agents
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
